First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

Judy Sing-Zan Wang,Serena De Vita,Janet L. Karlix,Carl Cook,Gillian M. Littlewood,Maureen Hattersley,Ganesh Moorthy,Helena Edlund,Giulia Fabbri,Kris Sachsenmeier,Chris Davison,Edwin Clark,Kathleen N. Moore,Todd Michael Bauer,Susanna Varkey Ulahannan,Manish R. Patel,Erika Paige Hamilton

First-in-human study of AZD5153, a small molecule inhibitor of bromodomain protein 4 (BRD4), in patients (pts) with relapsed/refractory (RR) malignant solid tumor and lymphoma: Preliminary data.

2019

Judy Sing-Zan Wang
Serena De Vita
Janet L. Karlix
Carl Cook
Gillian M. Littlewood
Maureen Hattersley
Ganesh Moorthy
Helena Edlund
Giulia Fabbri
Kris Sachsenmeier
Chris Davison
Edwin Clark
Kathleen N. Moore
Todd Michael Bauer
Susanna Varkey Ulahannan
Manish R. Patel
Erika Paige Hamilton

3085Background: BRD4 is a bromodomain and extraterminal (BET) protein that regulates oncogenic programs by modifying gene transcription and additional mechanisms. AZD5153 is a novel, reversible BRD...

Keywords:

Bromodomain
Refractory
Lymphoma
Small molecule
Human study
BRD4
Cancer research
Pathology
Medicine
in patient
solid tumor
Transcription (biology)
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations